ClinicalTrials.gov
ClinicalTrials.gov Menu

Stage IV Surgery Versus Best Medical Therapy (STG4SURG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01013623
Recruitment Status : Terminated (Lack of accrual, lack of continued funding.)
First Posted : November 16, 2009
Last Update Posted : September 26, 2012
Sponsor:
Collaborator:
Melanoma Research Alliance
Information provided by (Responsible Party):
John Wayne Cancer Institute

November 12, 2009
November 16, 2009
September 26, 2012
November 2009
September 2012   (Final data collection date for primary outcome measure)
Overall survival [ Time Frame: 3 interim analyses will be conducted when 75, 148, and 217 events (deaths) have occurred. The final analysis will be conducted when all 284 expected events have occurred. ]
Defined as time from randomization to death from any cause
Progression-free survival defined as time from randomization to disease recurrence in patients rendered disease-free by surgery, or time from randomization to RECIST-defined progression following best medical therapy, or death due to any cause. [ Time Frame: 3 interim analyses will be conducted when 75, 150, and 225 recurrences/progressions have occurred. The final analysis will be conducted when all 300 expected events have occurred. ]
Complete list of historical versions of study NCT01013623 on ClinicalTrials.gov Archive Site
  • Time to progression of initial metastatic sites (progression-free survival) [ Time Frame: 3 interim analyses will be conducted when 75, 148, and 217 primary events have occurred. The final analysis will be conducted when all 284 expected events have occurred. ]
    For this study, PFS is defined as the time from randomization to disease recurrence at initial metastatic site in patients rendered disease-free by surgery, or time from randomization to RECIST-defined progression of target lesions in patients receiving best medical therapy or those having residual disease following surgery.
  • Melanoma-specific survival [ Time Frame: 3 interim analyses will be conducted when 75, 148, and 217 recurrences/progressions have occurred. The final analysis will be conducted when all 284 expected events have occurred. ]
    Defined as time from randomization to death due to melanoma. Death due to causes other than melanoma are not considered events for this analysis.
  • Time to development of new metastatic sites. [ Time Frame: 3 interim analyses will be conducted when 75, 148, and 217 primary events have occurred. The final analysis will be conducted when all 284 expected events have occurred. ]
    This endpoint is defined as the time from randomization to disease recurrence at new metastatic sites in patients rendered disease-free by surgery, or time from randomization to the development of new metastatic sites of disease in patients in the best medical therapy group. Progression of existing lesions in the best medical therapy arm will not be considered an event for this endpoint.
  • Overall survival, defined as the time from randomization to death due to any cause. OS will be measured according to the initial randomization assignment (ITT analysis). [ Time Frame: 3 interim analyses will be conducted when 75, 150, and 225 recurrences/progressions have occurred. The final analysis will be conducted when all 300 expected events have occurred. ]
  • Melanoma-specific survival, defined as time from randomization to death due to melanoma. Death due to causes other than melanoma are not considered events for this analysis. [ Time Frame: 3 interim analyses will be conducted when 75, 150, and 225 recurrences/progressions have occurred. The final analysis will be conducted when all 300 expected events have occurred. ]
Not Provided
Not Provided
 
Stage IV Surgery Versus Best Medical Therapy
A Phase III, Randomized Trial of Surgical Resection With or Without BCG Versus Best Medical Therapy as Initial Treatment in Stage IV Melanoma
This study will establish the role of surgical versus nonsurgical approaches in patients whose melanoma has spread to distant sites. Results will help clinicians develop a standardized initial approach that prolongs survival and optimizes quality of life. Results also will indicate whether Bacillus Calmette-Guerin (BCG) postoperative immunotherapy significantly improves the outcome of patients treated with surgery.

This study is designed to examine the impact of surgical resection versus medical therapy as initial treatment therapy for patients with Stage IV melanoma. Surgical resection is thought to be efficacious in highly selected patients with solitary metastases, but not in patients with multiple sites of metastases. Even in those with solitary metastases, there is considerable debate among major melanoma centers over whether undergoing initial systemic medical therapy prior to surgical resection should be preferred to initial surgical resection upon Stage IV diagnosis. According to Dr. Dan Coit, Co-leader of the Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Institute in New York, a trial of initial medical therapy is their standard approach on the multidisciplinary melanoma service even for patients with solitary distant metastases (personal communication, 15 Dec 2009).

Many who favor upfront medical therapy believe that delay before surgical resection may avoid unnecessary surgery by identifying patients who progress early due to the outgrowth of occult metastases at multiple sites, which may make the patient unresectable.

This is a Phase III, randomized, international, multicenter study of metastasectomy with or without BCG versus best medical therapy as initial therapy in Stage IV melanoma. This study has three arms: surgical resection plus BCG as an immune adjuvant, surgical resection plus observation, and best medical therapy (BMT). Since no systemic medical therapy has been demonstrated to be superior to DTIC and multiple new therapies are being evaluated, the choice as to what constitutes best medical therapy will be determined by the individual investigator based on the standard of care for systemic medical therapy at that particular multicenter site. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments (e.g., DTIC or Temodar according to the standard of care at the multi-center site).

Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if appropriate, have surgical therapy; similarly, surgery patients may have additional surgical resection or receive medical therapy.

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Stage IV Resectable Melanoma
  • Procedure: Surgery
    surgical resection to remove all known disease
  • Procedure: Surgery plus 2 adjuvant doses of BCG
    Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
  • Other: best medical therapy
    Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
  • Active Comparator: Best Medical Therapy
    The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
    Intervention: Other: best medical therapy
  • Active Comparator: Surgery Alone
    The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
    Intervention: Procedure: Surgery
  • Active Comparator: Surgery + BCG
    The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
    Intervention: Procedure: Surgery plus 2 adjuvant doses of BCG
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
12
528
September 2012
September 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must provide informed written consent for participation.
  • At least 18 years of age
  • Have a minimum life expectancy (excluding melanoma) of 5 years.
  • All known disease must be surgically resectable in the opinion of a participating surgeon.
  • Must have a histologic diagnosis of Stage IV melanoma arising from a primary cutaneous site or visceral metastasis from an unknown primary site and be within 4 months of initial stage IV diagnosis.
  • Up to 3 visceral organs involved
  • Up to 6 lesions allowed
  • Must have ECOG performance status of 0 or 1.
  • Must be in good general health with no serious co-morbid illness. Good clinical judgment must be exercised in careful selection of patients who are candidates for surgical resection of distant metastases.
  • Laboratory values within 30 days of randomization:

    1. WBC >3,000/mm3
    2. Lymphocytes >800/mm3
    3. Platelets >100,000/mm3
    4. Creatinine <2.0 mg/dL
    5. Bilirubin <2.0 mg/dL
    6. Alkaline phosphatase < 2X upper limit of normal (ULN)
    7. SGOT < 2X ULN
    8. SGPT < 2X ULN
    9. LDH < 1.5X ULN

Exclusion Criteria:

  • Unresectable metastatic disease or more than 4 months since stage IV diagnosis.
  • Brain or bone metastatic sites.
  • History of primary uveal or mucosal melanoma.
  • Another concomitant diagnosis that limits life expectancy to less than 5 years.
  • Chronic immunosuppression due to inherited, acquired or iatrogenic immune defect. This includes active HIV, hepatitis, or use of immunosuppressive medications as a component of anti-rejection therapy for organ transplant, as treatment for an autoimmune disease.
  • More than 3 involved visceral organ sites or more than 6 metastatic lesions.
  • Psychiatric disorder or organic brain syndrome that might preclude participation in the protocol.
  • Diagnosis of other malignancy in the past 5 years except adequately treated low grade malignancies such as basal cell carcinoma, cutaneous squamous cell carcinoma, carcinoma-in-situ of the cervix, or other neoplasm that will not limit life expectancy to less than 5 years.
  • Serious cardiac, gastrointestinal, hepatic or pulmonary disease that would make surgical resection high-risk.
  • Pregnancy
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Israel,   Italy,   Netherlands,   United States
 
 
NCT01013623
MORD-STG4SURG-0409
3P01CA012582-35S1 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
John Wayne Cancer Institute
John Wayne Cancer Institute
Melanoma Research Alliance
Study Chair: Donald L. Morton, MD John Wayne Cancer Institute
John Wayne Cancer Institute
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP